Mylan Announces Final FDA Approval for Cetirizine Hydrochloride Tablets

PITTSBURGH, Dec. 28 Mylan Inc. (NYSE: MYL) todayannounced that Mylan Pharmaceuticals Inc. has received final approval from theU.S. Food and Drug Administration (FDA) for its Abbreviated New DrugApplication (ANDA) for Cetirizine Hydrochloride Tablets (OTC), 5 mg and 10 mg.

Cetirizine HCl Tablets are the generic version of Pfizer's Zyrtec(R)Tablets, which had U.S. sales of approximately $1.4 billion for the 12 monthsending Sept. 30, 2007.

This product will be shipped immediately.

Mylan Inc. is one of the world's leading quality generic and specialtypharmaceutical companies. The Company offers one of the industry's broadestand highest quality product portfolios, a robust product pipeline and a globalcommercial footprint through operations in more than 90 countries. Through itscontrolling interest in Matrix Laboratories Limited, Mylan has direct accessto one of the largest active pharmaceutical ingredient (API) manufacturers inthe world. Dey L.P., Mylan's fully integrated specialty business, provides theCompany with innovative and diversified opportunities in the respiratory andallergy therapeutic areas.

SOURCE Mylan Inc.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...